Table 3. Mean change in body weight from baseline to each post-baseline observation (ITT population).

Treatment day, Unit: kg	Tolvaptan (N = 46)			Placebo (N = 45)			Adjust group difference (95% CI)	p value
	N	Mean (SD)	Change (SD)	N	Mean (SD)	Change (SD)
Day 1 (baseline)	46	64.3 (14.7)	--	45	68.0 (14.5)	--	-3.77 (-9.84, 2.30)-	0.2206
Day 2	46	63.4 (14.7)	-0.84 (1.17)*	45	67.7 (14.3)	-0.31 (0.86)*	-0.55 (-0.98, -0.12)	0.0136
Day 3	45	62.6 (14.2)	-1.13 (1.52)*	43	67.9 (14.7)	-0.57 (1.06)*	-0.59 (-1.15, -0.02)	0.0416
Day 4	42	62.9 (14.2)	-1.20 (1.92)*	43	67.9 (14.7)	-0.54 (1.26)*	-0.69 (-1.40, -0.02)	0.0571
Post-dosing Day 5	43	62.1 (14.7)	-1.45 (2.16)*	40	67.8 (15.0)	-0.66 (1.31)*	-0.81 (-1.62, -0.01)	0.0476
EOS	46	62.9 (14.8)	-1.36 (2.13)*	45	67.4 (14.4)	-0.59 (1.27)*	-0.78 (-1.52, -0.04)	0.0394

Definition: EOS, end of study, the data represented with the result after 4-day tolvaptan treatment analyzed with the last observation carried forward (LOCF) method. 95% CI, confidence interval; SD, standard deviation.

p value: pair t-test for intragroup comparison; Post-Baseline ANCOVA Model: outcome = treatment + baseline level.

* With significant mean change compared to baseline value (intra p value < 0.05).